Welcome to our dedicated page for Checkpoint Therapeutics news (Ticker: CKPT), a resource for investors and traders seeking the latest updates and insights on Checkpoint Therapeutics stock.
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) is a clinical-stage biopharmaceutical company pioneering targeted immuno-oncology therapies for solid tumors. This page provides investors and healthcare professionals with comprehensive updates on CKPT's clinical developments, regulatory milestones, and strategic partnerships.
Access timely updates on key initiatives including PD-L1 inhibitor cosibelimab trials, EGFR-targeted therapies, and collaboration agreements. Our news collection covers essential developments such as clinical trial results, FDA communications, licensing deals, and financial updates - all critical for understanding CKPT's position in the competitive oncology market.
Bookmark this page for structured access to CKPT's progress in advancing non-chemotherapy treatments through innovative mechanisms. Stay informed about material events affecting the company's pipeline and market strategy without promotional bias.
Checkpoint Therapeutics (NASDAQ: CKPT) reported its 2020 financial results, highlighting a net loss of $23.1 million, down from $24.7 million in 2019. As of December 31, 2020, the company had $40.8 million in cash, up from $26.1 million a year prior. Significant progress was made on cosibelimab, with a 90% enrollment in its registration-enabling study for metastatic cutaneous squamous cell carcinoma (mCSCC) and a promising objective response rate of 51.4%. The company anticipates full top-line results in Q2 2021 and aims for a BLA submission to the FDA in 2022.
Checkpoint Therapeutics (NASDAQ: CKPT) announced that CEO James Oliviero will participate in the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021. The session will be available on-demand starting March 9, 2021, at 7:00 a.m. ET on Checkpoint's website for about 30 days.
The company is focused on developing immunotherapy treatments for solid tumors, notably evaluating cosibelimab, a novel anti-PD-L1 antibody, and CK-101, a targeted EGFR inhibitor for lung cancer.
Checkpoint Therapeutics (NASDAQ: CKPT) announced the formation of an independent Scientific Advisory Board featuring leading experts in oncology. This board will collaborate with Checkpoint's leadership to advance novel cancer treatments, specifically cosibelimab for skin and lung cancers, and CK-101 for lung cancer. Notable members include prominent figures from Harvard Medical School and Dana-Farber Cancer Institute. CEO James F. Oliviero expressed confidence in their impactful contributions to the company's mission of developing life-saving cancer therapies.
Checkpoint Therapeutics (NASDAQ: CKPT) announced that CEO James Oliviero will participate in three virtual investor conferences in January 2021. The events include the 10th Annual LifeSci Partners Corporate Access Event, where one-on-one meetings will occur from January 6-14. The H.C. Wainwright Virtual BioConnect Conference will feature an on-demand presentation starting January 11. Lastly, B. Riley Securities' Virtual Oncology Investor Conference presentation is set for January 21. Webcasts for select presentations will be available for 30 days on Checkpoint's website.
Checkpoint Therapeutics (CKPT) reported Q3 2020 financial results, highlighting positive interim outcomes from its clinical trial of cosibelimab for metastatic cutaneous squamous cell carcinoma (mCSCC). The company aims to complete enrollment for this trial by early 2021 and expects to release top-line results later in the year. Checkpoint expanded its cash runway with a $20.5 million financing, increasing cash reserves to $42 million. R&D expenses decreased to $2.5 million, while net loss narrowed to $4.9 million, or $0.09 per share, compared to the previous year's loss.
Samsung Biologics and Checkpoint Therapeutics have expanded their manufacturing partnership for the anti-PD-L1 antibody, cosibelimab, originally established in 2017. Under the new agreement, commercial-scale drug substance manufacturing will commence at Samsung's Plant 1 in 2021. This partnership aims to support Checkpoint's pivotal clinical trials and potential regulatory approvals for cosibelimab, which targets metastatic cutaneous squamous cell carcinoma. Checkpoint plans to release pivotal trial topline results by mid-2021.
Checkpoint Therapeutics (NASDAQ: CKPT) announced an underwriting agreement with H.C. Wainwright & Co. to sell 7,142,857 shares of common stock at $2.80 per share, expecting gross proceeds of $20 million. The offering's closing is anticipated around September 22, 2020, pending customary conditions. Additionally, the underwriter has a 30-day option to purchase up to 1,071,428 additional shares. Funds from the offering will support development activities for cosibelimab and other corporate needs.
Checkpoint Therapeutics (CKPT) announced interim results for cosibelimab, an anti-PD-L1 antibody targeting metastatic cutaneous squamous cell carcinoma (mCSCC). The data showed a 51.4% objective response rate (ORR) and 13.5% complete response rate, exceeding previous anti-PD-1 therapies. A favorable safety profile was noted, with lower severe adverse events. The company aims for market-disruptive pricing in the estimated $25 billion PD-(L)1 market. Full results are expected mid-2021, emphasizing the potential for cosibelimab to provide cost-effective treatment options.
Checkpoint Therapeutics (NASDAQ: CKPT) has announced the participation of President and CEO James F. Oliviero in three virtual investor conferences in September 2020. The events include:
- H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 3:30 p.m. EDT
- Cantor Virtual Global Healthcare Conference on September 16, 2020, at 10:00 a.m. EDT
- Lake Street Capital Markets 4th Annual Best Ideas Growth Conference on September 17, 2020
Webcasts will be available on Checkpoint’s website for approximately 30 days post-event.
FAQ
What is the current stock price of Checkpoint Therapeutics (CKPT)?
What is the market cap of Checkpoint Therapeutics (CKPT)?
